Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.30 |
| ▸ | DAO | P14920 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31153184 | 1.00 | KEAP1 (0.44) | KEAP1NFE2L2SLC9A1ALDH1A1MAOB | |
| SCHEMBL2566963 | 0.82 | KEAP1 (0.64) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL29406550 | 0.82 | KEAP1 (0.64) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL29406095 | 0.80 | CASP1 (0.47) | KEAP1NFE2L2SLC9A1ALDH1A1LMNA | |
| SCHEMBL25944824 | 0.80 | SMN1; SMN2 (0.45) | KEAP1NFE2L2SLC9A1ALDH1A1MAOB | |
| SCHEMBL10873823 | 0.80 | KEAP1 (0.62) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 | |
| Hydrochloric Acid SCHEMBL10552257 | 0.80 | KEAP1 (0.62) | KEAP1NFE2L2ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL566114 | 0.80 | CASP1 (0.47) | KEAP1NFE2L2SLC9A1ALDH1A1LMNA | |
| SCHEMBL919984 | 0.78 | KEAP1 (0.71) | KEAP1NFE2L2ALDH1A1MAOBALOX15 | |
| SCHEMBL31048928 | 0.78 | KEAP1 (0.71) | KEAP1NFE2L2ALDH1A1MAOBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0187376-A2 | 6,7-Disubstituted 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids | BAYER AG (DE) | 1986-07-16 | — | — | EP | claimed |
| US-12583854-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12195473-B2 | KRAS mutant protein inhibitors | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2025-01-14 | — | — | US | disclosed |
| EP-4466258-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| CN-116143804-B | Tetracyclic quinolone compound, pharmaceutically acceptable salt and application thereof | 核新生物医药(长春)有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-115192577-B | KRAS mutein inhibitors | 北京加科思新药研发有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-113286794-B | KRAS mutein inhibitors | 北京加科思新药研发有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117295742-A | New forms of compound I and their use | 北京加科思新药研发有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-2383268-A1 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | AstraZeneca AB (SE) | 2011-11-02 | — | — | EP | disclosed |
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
| EP-1846394-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | AstraZeneca AB (SE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082392-A1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| US-RE32975-E | FUNGICIDES, BACTERICIDES, FEED ADDITIVES | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | disclosed |
| US-4840954-A | BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-20 | — | — | US | disclosed |
| EP-0004279-B1 | PROCESS FOR THE PREPARATION OF 4-PYRIDONE-3-CARBOXYLIC ACIDS, 1-CYCLOPROPYL-4-PYRIDONE-3-CARBOXYLIC ACID DERIVATIVES AND MEDICINES CONTAINING THEM | BAYER AG (DE) | 1982-12-29 | — | — | EP | disclosed |
| US-4284629-A | ANIMAL GROWTH REGULATORS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-08-18 | — | — | US | disclosed |
| EP-0004279-A1 | Process for the preparation of 4-pyridone-3-carboxylic acids, 1-cyclopropyl-4-pyridone-3-carboxylic acid derivatives and medicines containing them | BAYER AG (DE) | 1979-10-03 | — | — | EP | disclosed |
| US-4089960-A | Antiemetic, psychosomatic and antipsychotic heterocyclic pyridine carboxamides | CIBA-GEIGY CORPORATION (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139561-A1 | e.g. 6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-5-fluoro-2-(1-(4-fluorophenyl)ethylamino) nicotinonitrile; tropomyosin-related kinases (Trk's) inhibitor; anticarcinogenic agent; hormone related cancer, leukemia; antiinflammatory agent; arthritis, restenosis; autoimmune diseases | CNKSR1, LTK, MUSK | KEAP1 2331/4885NFE2L2 2337/4885SLC9A1 4139/4885 |
| US-12195473-B2 | KRAS mutant protein inhibitors | KRAS, NRAS, APC | KEAP1 306/4885NFE2L2 3066/4885SLC9A1 4226/4885 |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | H1-3, H1-2, H1-4 | KEAP1 2531/4885NFE2L2 1120/4885SLC9A1 2781/4885 |
| US-12583854-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, APC | KEAP1 688/4885NFE2L2 1284/4885SLC9A1 200/4885 |
| US-20230357233-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | KEAP1 549/4885NFE2L2 1011/4885SLC9A1 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.